Crayon Hits 3 Key Steps on AWS Winning Streak
Crayon, a global leader in digital transformation, today announced it has hit four key growth milestones during its 10-year anniversary for artificial intelligence (AI) innovation. Despite the challenges posed by market dynamics, the company has prevailed, attributing its success to a strategic partnership with Amazon Web Services (AWS).
Last year, the COVID-19 tech bubble finally burst causing chaos in the global IT market with 262,000 employeesi being laid off. According to Gartner®ii, “The overall IT spending growth rate for 2023 was 3.3%, only a 0.3% increase from 2022. This was largely due to change fatigue among CIOs. Momentum will regain in 2024, with overall IT spending increasing 6.8%.” In May 2023, amidst global market fluctuations, Crayon strengthened its position by entering a four-year Strategic Collaboration Agreement with AWSiii. The agreement expanded Crayon’s existing AWS Premier Tier Services Partner role and sought to create a Crayon team of 500 AWS-certified experts worldwide.
In the year since, Crayon has hit three key milestones:
- Earned two new AWS competencies – SaaS Consulting and Generative AI Services – taking its total to seven.
- Signed its thousandth customer onto its managed billing service.
Crayon helps companies and ISVs fix their foundations using a step-by-step approach. In just a few hours, customers can benefit from a well-architected landing zone, a task that historically takes weeks to complete. Crayon has created a library of AWS Architected Accelerators to help customers scale. Using its FinOps expertise, Crayon typically helps customers cut their IT costs by 30%, as well as gain real-time 360° visibility of their cloud infrastructure.
This year, Crayon celebrates ten years of AI innovation. During this time, it has delivered more than 300 live Applied AI projects and managed over 90 GenAI projects. Commenting on the key milestone, Florian Rosenberg, CTO at Crayon said, “There’s not much we don’t know about how to build a modern data platform that allows our customers to build AI use cases, which improve their business processes or create new revenue streams.”
Melissa Mulholland, CEO, Crayon, believes there is a bigger reason for Crayon’s success than technical skills alone: “These milestones are a testament to our team’s dedication and expertise in leveraging AWS technologies to deliver impactful solutions. Through our premier-tier partner status investment, we empower customers of all sizes to access AWS programs that mitigate migration and modernization costs. At Crayon, customer service is paramount – we ensure every client receives optimized platforms and exceptional experiences.”
About Crayon
Headquartered in Oslo, Norway, with a global presence spanning 46 countries and a dedicated team of 4,000 professionals, Crayon champions IT optimization and innovation. We are a customer-first company providing return on investment on software and cloud spend by empowering our customers to strategically acquire and optimize software investments, embrace cloud and AI technologies, and drive innovation through enhanced efficiency.
i According to Statista, as of December 2023, more than 262,000 employees at tech companies worldwide had been laid off during the year across more than 1,180 firms. https://www.statista.com/topics/10370/tech-sector-layoffs/
ii Gartner® Press release: “Gartner Forecasts Worldwide IT Spending to Grow 6.8% in 2024”, 17 January 2024. https://www.gartner.com/en/newsroom/press-releases/01-17-2024-gartner-forecasts-worldwide-it-spending-to-grow-six-point-eight-percent-in-2024. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
iiiAWS market share in the worldwide cloud infrastructure market amounted to 31%, compared to its main rival, Microsoft, which hit an all-time high of 23% in Q1 2024.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003229346/en/
Contacts
Linda Rønningen
+47 405 55 278
linda.ronningen@crayon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom